GILD Receives FDA Approval
Gilead Sciences receives FDA approval for Trodelvy to treat triple-negative breast cancer
GILD Gilead Sciences Receives FDA Approval For Its Trodelvy Antibody-Dug Conjugate To Treat Adult Patients With Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer